Shares of Biogen Inc. BIIB inched 0.49% higher to $185.68 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...

A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...

Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.

A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology ... Show Alzheimer’s Disease Does Not Stop Progressing After Plaque Clearance.